No Data
No Data
Top-rated Biotechs With Negative Enterprise Values
This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Truist Financial Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $18
Truist Sees 'Significant Upside' for Larimar Therapeutics, Starts With a Buy
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target
Larimar Therapeutics Aligns Executive Incentives With Milestones
felixfella OP : couldn't go up if it was riding on a airplane...